Loading...
A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Paplomata, E Bachelot, T Mueller, V Murias, C Murthy, RK Okines, AFC Walker, LN Oliveira, AMAD
Paplomata, E
Bachelot, T
Mueller, V
Murias, C
Murthy, RK
Okines, AFC
Walker, LN
Oliveira, AMAD
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 58.22 KB
Keywords
Type
Meetings and Proceedings
Citation
Paplomata E, Bachelot T, Mueller V, Murias C, Murthy RK, Okines AFC, et al. 198TiP A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Ann Oncol. 2019;30(Supplement_3):63-4.